Sebia Receives U S FDA Clearance for the FLC Kappa & Lambda Assays finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S..
Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma even in those with high-risk features.
100% overall response rate and 67% complete response rate observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100% .
The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.